Cidara Therapeutics (NASDAQ: CDTX) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Cidara Therapeutics to related businesses based on the strength of its risk, profitability, valuation, dividends, earnings, analyst recommendations and institutional ownership.
This table compares Cidara Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cidara Therapeutics Competitors||-5,189.81%||-162.78%||-35.24%|
This table compares Cidara Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cidara Therapeutics||N/A||-$48.16 million||-2.09|
|Cidara Therapeutics Competitors||$290.27 million||$35.99 million||56.15|
Cidara Therapeutics’ competitors have higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
55.5% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 18.9% of Cidara Therapeutics shares are held by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for Cidara Therapeutics and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cidara Therapeutics Competitors||919||3337||11841||237||2.70|
Cidara Therapeutics currently has a consensus target price of $13.50, suggesting a potential upside of 90.14%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 40.59%. Given Cidara Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Cidara Therapeutics is more favorable than its competitors.
Cidara Therapeutics beats its competitors on 8 of the 12 factors compared.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc., formerly K2 Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections. Its product portfolio consists of over two formulations of its echinocandin, CD101. CD101 IV is a long-acting therapy for the treatment and prevention of serious, invasive fungal infections. CD101 topical, its second product candidate, is being developed for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC (RVVC), a prevalent mucosal infection. Its immunotherapy technology platform, Cloudbreak, is used to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. The Company is also developing CD201, its bispecific antimicrobial immunotherapy.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.